for autism is taking place at Saint Peter's University
Hospital.
"We are targeting the symptoms of autism," said Dr.
Joan Fallon, founder of Curemark LLC, a drug-r
esearch and development company located in Rye,
N.Y. The company is testing its new product at 13
locations nationwide.
The testing being conducted at Saint Peter's
involves 170 youngsters, hospital spokesman Phil
Hartman said.
Fallon said the test pool covers children age 3 to 8.
She said she expects results "sometime early next
year."
For competitive reasons, she did not want to
discuss specifics of the product, called for now
"CM-AT," for "Curemark's autism treatment."
She said the testing started about three months
ago. Dr. Barbie Zimmerman-Bier of Saint Peter's, who
is running the study, said: "Subjects heard about it
and they got word from support groups. ... There
was a screening process to see if they were eligible.
They had to be between 3 and 8."
Regarding how children are being tested to see if
the drug works and how frequently they are being
checked, Fallon said, "We use standardized,
validated measures to look at change in their
behaviors."
Zimmerman-Bier reported said children were seen
at the beginning of the study, then at two weeks,
four weeks, eight weeks and 12 weeks.
Read More @ http://www.app.com/apps/pbcs.dll/article?AID=2010101118156
No comments:
Post a Comment